EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

Meghana Yellanki, Jennifer La, Danne C Elbers, Nhan V Do, Channing J Paller iD, Nathanael R Fillmore iD, Martin W Schoen iD

The Prostate · 2026-12 · 86 (16) · 1637-1644

DOI: 10.1002/pros.70247 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 17.09.2026. Verfasst von Meghana Yellanki und 6 weiteren Autor:innen. Beteiligte Einrichtung: VA Boston Healthcare System, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Benzamides, Prostatic Neoplasms, Castration-Resistant, Nitriles, Phenylthiohydantoin. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: U.S. Department of Defense, VA Cooperative Studies Program, Office of Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain. This study aims to determine whether one ARPI is associated with longer overall survival (OS) than the other, expanding upon prior work through inclusion of a contemporary patient cohort and examination of how comorbidities influence OS.

Methods

Using data from the nationwide Veterans Affairs (VA) healthcare system, we identified 8859 veterans with mCRPC treated with either abiraterone or enzalutamide between September 2014 and September 2022. Patients with prior docetaxel exposure were excluded, and frailty was defined using the VA Frailty Index (VA‐FI). Analyses were weighted for clinical covariates, including age, race, and BMI, using IPTW. Kaplan–Meier analysis was used to compare OS between treatment groups.

Results

Among frail patients with mCRPC, enzalutamide treatment was associated with longer OS compared to abiraterone (22.8 vs. 20.9 months, p = 0.001). Similarly, enzalutamide was associated with longer OS than abiraterone among patients with cardiovascular disease or diabetes (26.3 vs. 23.9 months, p = 0.023) and among patients without cardiovascular disease or diabetes (30.0 vs. 28.0 months, p = 0.019).

Conclusions

Enzalutamide was associated with improved OS compared to abiraterone in frail patients with mCRPC, regardless of comorbid cardiovascular disease or diabetes. These findings highlight the importance of considering specialized patient populations, including frailty and comorbidity profiles, in ARPI selection and clinical care. Trial Registration: NA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzamidesProstatic Neoplasms, Castration-ResistantNitrilesPhenylthiohydantoinAndrostenesFrailtyHumansMaleAgedVeteransComorbidityAged, 80 and overTreatment OutcomeUnited StatesMiddle AgedNeoplasm Metastasis

Stichwörter der Autor:innen

Veterans Health Administrationabirateroneandrogen receptor pathway inhibitorsenzalutamidefrailtymetastatic castration‐resistant prostate cancersurvival outcomes

Substanzen

BenzamidesenzalutamideNitrilesPhenylthiohydantoinabirateroneAndrostenes

Autor:innen und Institutionen

  • VA Boston Healthcare System, Boston, Massachusetts, USA.
  • Boston University Chobanian & Avedesian School of Medicine, Boston, Massachusetts, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Harvard Medical School, Boston, Massachusetts, USA.
  • VA St. Louis Healthcare System, St. Louis, Missouri, USA.
  • Division of Hematology/Oncology, Department of Medicine, Saint Louis University School of Medicine, St. Louis, Missouri, USA.

ORCID-Profile: Channing J Paller, Nathanael R Fillmore, Martin W Schoen

Förderung

  • U.S. Department of Defense
  • VA Cooperative Studies Program
  • Office of Research and Development
  • U.S. Department of War

Zitieren

APA

Yellanki, M., La, J., Elbers, D. C., Do, N. V., Paller, C. J., Fillmore, N. R., & Schoen, M. W. (2026). Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer. The Prostate, 86(16), 1637-1644. https://doi.org/10.1002/pros.70247

Vancouver

Yellanki M, La J, Elbers DC, Do NV, Paller CJ, Fillmore NR, et al. Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer. The Prostate. 2026;86(16):1637-1644. doi:10.1002/pros.70247

BibTeX
@article{Yellanki2026,
  author = {Yellanki, Meghana and La, Jennifer and Elbers, Danne C and Do, Nhan V and Paller, Channing J and Fillmore, Nathanael R and Schoen, Martin W},
  title = {Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {16},
  pages = {1637--1644},
  doi = {10.1002/pros.70247}
}
Kostenlos starten →